Antiretroviral therapies in women after single-dose nevirapine exposure

New England Journal of Medicine

Volumn 363, Issue 16, 2010, Pages 1499-1509

  Lockman, S ^a,b,c   Hughes, M D ^b   McIntyre, J ^d   Zheng, Y ^b   Chipato, T ^g   Conradie, F ^e   Sawe, F ^h   Asmelash, A ^c   Hosseinipour, M C ⁱ   Mohapi, L ^f   Stringer, E ^j   Mngqibisa, R ^k   Siika, A ^l   Atwine, D ^m   Hakim, J ^g   Shaffer, D ^h   Kanyama, C ⁱ   Wools Kaloustian, K ⁿ   Salata, R A ^o   Hogg, E ^p   Alston Smith, B ^q   Walawander, A ^r   Purcelle Smith, E ^q   Eshleman, S ^s   Rooney, J ^t   Rahim, S ^u   Mellors, J W ^v   Schooley, R T ^w   Currier, J S ^x   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^d ANOVA HEALTH INSTITUTE   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^h KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

ⁱ UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^j CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^k UNIVERSITY OF KWAZULU NATAL   (South Africa)

^l MOI UNIVERSITY   (Kenya)

^m JOINT CLINICAL RESEARCH CENTRE   (Uganda)

ⁿ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o CASE WESTERN RESERVE UNIVERSITY   (United States)

^p SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^q NATIONAL INSTITUTES OF HEALTH   (United States)

^r FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^s DEPARTMENT OF PATHOLOGY   (United States)

^t GILEAD SCIENCES   (United States)

^u ABBOTT LABORATORIES   (United States)

^v PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^w UNIVERSITY OF CALIFORNIA   (United States)

^x UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALUVIA; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; CREATININE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; POTASSIUM; SODIUM; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VIRUS RNA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DEOXYCYTIDINE; EMTRICITABINE; LOPINAVIR; PHOSPHONIC ACID DERIVATIVE; PYRIMIDINONE DERIVATIVE; RITONAVIR; TENOFOVIR;

ACUTE PANCREATITIS; ADULT; AFRICA; ARTICLE; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DEATH; DENTAL CARE; DIARRHEA; DRUG EFFECT; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KIDNEY FAILURE; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALARIA; NAUSEA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PAIN; PATIENT COMPLIANCE; PERINATAL DRUG EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUBERCULOSIS; VERTICAL TRANSMISSION; VOMITING; WEIGHT BEARING; ANALOGS AND DERIVATIVES; DRUG COMBINATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; KAPLAN MEIER METHOD; MORTALITY; NONPARAMETRIC TEST; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; STATISTICAL MODEL; TRANSMISSION; TREATMENT FAILURE; YOUNG ADULT;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LOPINAVIR; NEVIRAPINE; ORGANOPHOSPHONATES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRIMIDINONES; RITONAVIR; STATISTICS, NONPARAMETRIC; TREATMENT FAILURE; YOUNG ADULT;

EID: 77957945728     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0906626     Document Type: Article

References (37)

1. AIDS epidemic update: November 2009. Geneva: UNAIDS.
2. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2008. Geneva: World Health Organization, 2008.
3. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants recommendations for a public health approach - 2010 version. Geneva: World Health Organization, 2010.
4. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 2004;35:126-30. (Pubitemid 38133734)
5. Kassaye S, Lee E, Kantor R, et al. Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis. AIDS Res Hum Retroviruses 2007; 23:1055-61. (Pubitemid 47492348)
6. Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr 2006;42:610-3.
7. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005;192:16-23. (Pubitemid 40863852)
8. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 2006;20:995-1002.
9. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A 2006;103:7094-9.
10. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis 2006; 193:482-7.
11. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007;370:1698-705. [Erratum, Lancet 2008;371:650.]
12. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med 2009;6(10):e1000172.
13. van Zyl GU, Claassen M, Engelbrecht S, et al. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. J Med Virol 2008;80:942-6. (Pubitemid 351657002)
14. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15: 1951-7.
15. Morris L, Martinson N, Pillay C, et al. Persistence of nevirapine resistance mutations 6 months following single dose nevirapine. Presented at the XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004. abstract. (http://gateway .nlm.nih.gov/MeetingAbstracts/ma?f= 102280637.html.)
16. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192:24-9.
17. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007;195:711-5. (Pubitemid 46273046)
18. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004;351:229-40.
19. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevir apine. N Engl J Med 2007;356:135-47.
20. Chi BH, Sinkala M, Stringer EM, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 2007;21:957-64.
21. Coovadia A, Hunt G, Abrams EJ, at al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to non-nucleoside reverse-transcriptase inhibitor - based therapy. Clin Infect Dis 2009;48: 462-72.
22. Stringer JS, McConnell MS, Kiarie J, et al. Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study. PLoS Med. 2010;7(2):e1000233.
23. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2010 revision. Geneva: World Health Organization, 2010.
24. Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events. Baltimore: National Institutes of Health, 2004.
25. Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-85.
26. East 5 user manual. Cambridge, MA: Cytel, 2007.
27. Jourdain G, Ngo-Giang-Huong N, Tungyai P, et al. Exposure to intrapartum single-dose nevirapine and subsequent maternal 6-month response to NNRTI-based regimens. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004. abstract. (http://www. retroconference.org/2004/cd/Abstract/41LB.htm.)
28. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-63.
29. Rey D, Hoen B, Chavanet P, et al. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 2009;63: 380-8.
30. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-46.
31. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006;368:476-82. [Erratum, Lancet 2006;368:1238.]
32. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-106.
33. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral- naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-55.
34. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008;22:1389-97.
35. Coovadia A, Hunt G, Abrams EJ, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 2009;48:462-72.
36. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005;192: 30-6.
37. Eshleman SH, Guay LA, Wang J, et al. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr 2005;40:24-9. (Pubitemid 41233200)